Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* obese (body mass index \[BMI\] ≥30 kg/m² and ≤40 kg/m²) male participants and female participants of non-childbearing potential~* has been diagnosed with T2D (Panel B)~* is not actively participating in a weight loss program~Exclusion Criteria:~* has a history of clinically-significant disease (other than T2D)~* has a history of cancer~* has estimated creatinine clearance ≤60 mL/min~* is unable to refrain from or anticipates the use of any prescription or non-prescription medication~* consumes excessive amounts of alcohol or caffeine~* has participated in a previous omarigliptin study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Omarigliptin (Type: EXPERIMENTAL): Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
- Healthy Placebo (Type: PLACEBO_COMPARATOR): Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
- T2D Omarigliptin (Type: EXPERIMENTAL): Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
- T2D Placebo (Type: PLACEBO_COMPARATOR): Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).

Based on this trial design, predict the completion outcome and termination type (if applicable).